View in EDS PDF Full Text

Clinical perspectives of emerging pathogens in bleeding disorders.

Saved in:
Bibliographic Details
Title: Clinical perspectives of emerging pathogens in bleeding disorders.
Authors: Ludlam CA (AUTHOR), Powderly WG (AUTHOR), Bozzette S (AUTHOR), Diamond M (AUTHOR), Koerper MA (AUTHOR), Kulkarni R (AUTHOR), Ritchie B (AUTHOR), Siegel J (AUTHOR), Simmonds P (AUTHOR), Stanley S (AUTHOR), Tapper ML (AUTHOR), von Depka M (AUTHOR), Ludlam, Christopher A (AUTHOR), Powderly, William G (AUTHOR), Bozzette, Samuel (AUTHOR), Diamond, Michael (AUTHOR), Koerper, Marion A (AUTHOR), Kulkarni, Roshni (AUTHOR), Ritchie, Bruce (AUTHOR), Siegel, Jamie (AUTHOR)
Source: Lancet. 1/21/2006, Vol. 367 Issue 9506, p252-261. 10p.
Abstract: As a result of immunological and nucleic-acid screening of plasma donations for transfusion-transmissible viruses, and the incorporation of viral reduction processes during plasma fractionation, coagulation-factor concentrates (CFC) are now judged safe in terms of many known infectious agents, including hepatitis B and C viruses, HIV, and human T-cell lymphotropic virus. However, emerging pathogens could pose future threats, particularly those with blood-borne stages that are resistant to viral-inactivation steps in the manufacturing process, such as non-lipid-coated viruses. As outlined in this Review, better understanding of infectious diseases allows challenges from newly described agents of potential concern in the future to be anticipated, but the processes of zoonotic transmission and genetic selection or modification ensure that plasma-derived products will continue to be subject to infectious concerns. Manufacturers of plasma-derived CFC have addressed the issue of emerging infectious agents by developing recombinant products that limit the need for human plasma during production. Such recombinant products have extended the safety profile of their predecessors by ensuring that all reagents used for cell culture, purification steps, and stabilisation and storage buffers are completely independent of human plasma. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 106226448
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Clinical perspectives of emerging pathogens in bleeding disorders.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Ludlam+CA%22">Ludlam CA</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Powderly+WG%22">Powderly WG</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bozzette+S%22">Bozzette S</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Diamond+M%22">Diamond M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Koerper+MA%22">Koerper MA</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kulkarni+R%22">Kulkarni R</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ritchie+B%22">Ritchie B</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Siegel+J%22">Siegel J</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Simmonds+P%22">Simmonds P</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Stanley+S%22">Stanley S</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tapper+ML%22">Tapper ML</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22von+Depka+M%22">von Depka M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ludlam%2C+Christopher+A%22">Ludlam, Christopher A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Powderly%2C+William+G%22">Powderly, William G</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bozzette%2C+Samuel%22">Bozzette, Samuel</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Diamond%2C+Michael%22">Diamond, Michael</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Koerper%2C+Marion+A%22">Koerper, Marion A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kulkarni%2C+Roshni%22">Kulkarni, Roshni</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ritchie%2C+Bruce%22">Ritchie, Bruce</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Siegel%2C+Jamie%22">Siegel, Jamie</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 1/21/2006, Vol. 367 Issue 9506, p252-261. 10p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: As a result of immunological and nucleic-acid screening of plasma donations for transfusion-transmissible viruses, and the incorporation of viral reduction processes during plasma fractionation, coagulation-factor concentrates (CFC) are now judged safe in terms of many known infectious agents, including hepatitis B and C viruses, HIV, and human T-cell lymphotropic virus. However, emerging pathogens could pose future threats, particularly those with blood-borne stages that are resistant to viral-inactivation steps in the manufacturing process, such as non-lipid-coated viruses. As outlined in this Review, better understanding of infectious diseases allows challenges from newly described agents of potential concern in the future to be anticipated, but the processes of zoonotic transmission and genetic selection or modification ensure that plasma-derived products will continue to be subject to infectious concerns. Manufacturers of plasma-derived CFC have addressed the issue of emerging infectious agents by developing recombinant products that limit the need for human plasma during production. Such recombinant products have extended the safety profile of their predecessors by ensuring that all reagents used for cell culture, purification steps, and stabilisation and storage buffers are completely independent of human plasma. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=106226448
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/s0140-6736(06)68036-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 252
    Titles:
      – TitleFull: Clinical perspectives of emerging pathogens in bleeding disorders.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ludlam CA
      – PersonEntity:
          Name:
            NameFull: Powderly WG
      – PersonEntity:
          Name:
            NameFull: Bozzette S
      – PersonEntity:
          Name:
            NameFull: Diamond M
      – PersonEntity:
          Name:
            NameFull: Koerper MA
      – PersonEntity:
          Name:
            NameFull: Kulkarni R
      – PersonEntity:
          Name:
            NameFull: Ritchie B
      – PersonEntity:
          Name:
            NameFull: Siegel J
      – PersonEntity:
          Name:
            NameFull: Simmonds P
      – PersonEntity:
          Name:
            NameFull: Stanley S
      – PersonEntity:
          Name:
            NameFull: Tapper ML
      – PersonEntity:
          Name:
            NameFull: von Depka M
      – PersonEntity:
          Name:
            NameFull: Ludlam, Christopher A
      – PersonEntity:
          Name:
            NameFull: Powderly, William G
      – PersonEntity:
          Name:
            NameFull: Bozzette, Samuel
      – PersonEntity:
          Name:
            NameFull: Diamond, Michael
      – PersonEntity:
          Name:
            NameFull: Koerper, Marion A
      – PersonEntity:
          Name:
            NameFull: Kulkarni, Roshni
      – PersonEntity:
          Name:
            NameFull: Ritchie, Bruce
      – PersonEntity:
          Name:
            NameFull: Siegel, Jamie
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 21
              M: 01
              Text: 1/21/2006
              Type: published
              Y: 2006
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 367
            – Type: issue
              Value: 9506
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1